JPM Global Healthcare C (acc) EUR |
Performance History | 30/04/2024 |
Growth of 1,000 (EUR) |
Fund | 13.8 | 21.0 | -3.0 | -0.1 | 7.4 | |
+/-Cat | 2.6 | 4.4 | 6.7 | 0.7 | 4.0 | |
+/-Idx | - | -5.0 | -3.2 | 0.1 | 1.1 | |
Category: Sector Equity Healthcare | ||||||
Benchmarks: Morningstar Gbl Health TME ... |
Key Stats | ||
NAV 17/05/2024 | EUR 198.87 | |
Day Change | -0.36% | |
Morningstar Category™ | Sector Equity Healthcare | |
ISIN | LU1048171810 | |
Fund Size (Mil) 17/05/2024 | USD 4226.39 | |
Share Class Size (Mil) 17/05/2024 | EUR 129.39 | |
Max Initial Charge | - | |
Ongoing Charge 06/12/2023 | 0.99% |
Investment Objective: JPM Global Healthcare C (acc) EUR |
To achieve a return by investing primarily in pharmaceutical, biotechnology, healthcare services, medical technology and life sciences companies ("Healthcare Companies"), globally. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Holly Fleiss 09/06/2022 | ||
Dominic Valder 05/10/2022 | ||
Click here to see others | ||
Inception Date 26/03/2014 |
Advertisement |
Benchmarks | |
Fund Benchmark | Morningstar Benchmark |
MSCI World/Health Care NR USD | Morningstar Gbl Health TME NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for JPM Global Healthcare C (acc) EUR | 31/03/2024 |
|
|
Top 5 Holdings | Sector | % |
Eli Lilly and Co | Healthcare | 9.01 |
UnitedHealth Group Inc | Healthcare | 7.66 |
Novo Nordisk A/S Class B | Healthcare | 5.96 |
AbbVie Inc | Healthcare | 5.17 |
Regeneron Pharmaceuticals Inc | Healthcare | 4.54 |
Increase Decrease New since last portfolio | ||
JPM Global Healthcare C (acc) EUR |